

Accepted Manuscript

“Treatments, outcomes and validity of prognostic scores in patients with sarcomatoid renal cellcarcinoma: a twenty years’ single institution experience”

Clement Korenbaum, Laure Pierard, MD, Alicia Thiéry, MD, Fleur Story, Véronique Lindner, MD, PhD, Hervé Lang, MD, PhD, Jean-Emmanuel Kurtz, MD, PhD, Philippe Barthélémy, MD, PhD

PII: S1558-7673(17)30391-9

DOI: [10.1016/j.clgc.2017.12.005](https://doi.org/10.1016/j.clgc.2017.12.005)

Reference: CLGC 982

To appear in: *Clinical Genitourinary Cancer*


Received Date: 9 October 2017

Revised Date: 29 November 2017

Accepted Date: 15 December 2017

Please cite this article as: Korenbaum C, Pierard L, Thiéry A, Story F, Lindner V, Lang H, Kurtz J-E, Barthélémy P, “Treatments, outcomes and validity of prognostic scores in patients with sarcomatoid renal cellcarcinoma: a twenty years’ single institution experience”, *Clinical Genitourinary Cancer* (2018), doi: 10.1016/j.clgc.2017.12.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title : "Treatments, outcomes and validity of prognostic scores in patients with sarcomatoid renal cell carcinoma: a twenty years' single institution experience."

Autors : Clement Korenbaum¹, Laure Pierard (MD)¹, Alicia Thiéry (MD)², Fleur Story³, Véronique Lindner (MD, PhD)⁴, Hervé Lang (MD,PhD)³, Jean-Emmanuel Kurtz (MD, PhD)¹, Philippe Barthélémy (MD, PhD)¹

1: Department of medical oncology, Hôpitaux Universitaires de Strasbourg, France

2: Department of epidemiology, Centre Paul Strauss, Strasbourg, France

3: Department of urology, Hôpitaux Universitaires de Strasbourg, France

4: Department of pathology, Hôpitaux Universitaires de Strasbourg, France

Manuscript

Title: Treatments, outcomes and validity of prognostic scores in patients with sarcomatoid renal cell carcinoma: a twenty years' single institution experience.

Abstract

Introduction

Metastatic renal cell carcinoma (RCC) with a sarcomatoid component is a rare disease associated with a poor prognosis. We report the outcomes of 47 metastatic sarcomatoid RCC (SRCC) treated with different modalities including chemotherapy, tyrosine kinase inhibitors or immunotherapy over two decades in a French cancer center. Furthermore, we assessed the validity of prognostic scores in this subset of RCC.

Patients and methods

Patients (pts) were retrospectively identified from the database of the pathology department of the University Hospital of Strasbourg. We enrolled all RCC with a sarcomatoid component diagnosed between 1995 and 2016. Pts with non-metastatic RCC were excluded. Recorded variables included: Clinical stage, metastatic sites, pathologic stage, type of treatments, prognostic groups and survival data. The primary endpoint was overall survival (OS). The institutional Ethical Committee approved the study protocol.

Results

Out of 104 pts with SRCC, forty-seven pts with metastatic SRCC were included. The median age was 60 years (range, 41 to 77 years). Median length of follow up was 34 months (range, 1 to 180 months). 55% of pts had known metastases at diagnosis. Lung represented the first metastatic site (70%) followed by glandular (28%), bone (23%), liver (21%) and brain (6%). 15% of pts received immunotherapy including cytokines based therapy (n=7pts), or checkpoint inhibitors (n=2). Moreover, 7 pts received chemotherapy. Five pts received no systemic treatment regarding to their performance status. Out of 42 treated pts, 2 pts achieved complete response and 9 partial responses

Download English Version:

<https://daneshyari.com/en/article/8613741>

Download Persian Version:

<https://daneshyari.com/article/8613741>

[Daneshyari.com](https://daneshyari.com)